A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

February 28, 2027

Conditions

Locally Advanced, Recurrent or Metastatic Malignancies

Interventions

DRUG

SSGJ-705

anti-PD-1 and anti-HER2 bispecific antibody

Trial Locations (1)

RECRUITING

Affiliated Cancer Hospital of Shandong First Medical University, Jinan

All Listed Sponsors

lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY